US Patent

US12433895 — Therapeutically active compounds and their methods of use

Method of Use · Assigned to Servier Pharmaceuticals LLC · Expires 2034-07-11 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for treating cancer, specifically compounds useful for treating cancer and methods of administering them to a subject.

USPTO Abstract

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Drugs covered by this patent

Voranigo (VORASIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4286`	—	Voranigo
`U-4286`	—	Voranigo

Patent Metadata

Patent number: US12433895
Jurisdiction: US
Classification: Method of Use
Expires: 2034-07-11
Drug substance claim: No
Drug product claim: No
Assignee: Servier Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.